Qfa thrombin

Manufactured by Werfen

Sourced in Italy

The QFA thrombin is a laboratory instrument used for the quantitative detection and measurement of thrombin, a key enzyme involved in the blood coagulation process. It provides accurate and reliable results to support clinical diagnostic and research applications.

Automatically generated - may contain errors

Lab products found in correlation

Acl top 500, by Werfen (4 mentions) Hemosil d dimer hs, by Werfen (2 mentions) Elisa, by Siemens (1 mentions) Enzygnost, by Siemens (1 mentions) Hemosil fviii c, by Werfen (1 mentions)

4 protocols using qfa thrombin

Fibrinogen Levels in Moli-sani Cohort

Check if the same lab product or an alternative is used in the 5 most similar protocols

Between July 2014 and March 2017, frozen citrated plasma samples of about 2,500 Moli-sani participants selected for the case-cohort study (1000 cases of any cancer, including CRC and 1,500 subcohort individuals), were express-shipped in several batches on dry ice to the Hemostasis and Thrombosis Laboratory of the Division of Immunohematology and Transfusion Medicine, Papa Giovanni XXIII Hospital in Bergamo. Fibrinogen levels were measured, in frozen citrated plasma samples, with a test based on the Clauss method, on the coagulation system ACL TOP 500 (Q.F.A. Thrombin; Werfen). Quality controls included high and low plasma samples, provided by the kit, and a home-made normal pool plasma. Regarding the latter, the CVs for normal and abnormal value were 6.1 and 4.3% for intra- and 6.7 and 5.1% for inter-assay, respectively.
Even if the latter procedure could theoretically influence the laboratory data, it has been documented that freezing and long-term storing seems to have minimal effects on fibrinogen levels and is irrelevant for clinical interpretation (37 (link)).

Parisi R., Panzera T., Russo L., Gamba S., De Curtis A., Di Castelnuovo A., Marchetti M., Cerletti C., Falanga A., de Gaetano G., Donati M.B., Iacoviello L, & Costanzo S. (2022). Fibrinogen levels in relation to colorectal cancer onset: A nested case-cohort study from the Moli-sani cohort. Frontiers in Cardiovascular Medicine, 9, 1009926.

+ Open protocol

+ Expand

Thrombin Generation Assessment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

TG was evaluated by the calibrated automated thrombogram method at 5pM Tissue Factor (CAT assay, Stago) [17 (link),27 (link)]. All plasma samples were tested in duplicate. The following parameters of TG curve were considered: lag-time, endogenous thrombin potential (ETP), peak height (peak), and time to peak (ttp). Plasma levels of D-dimer (HemosIL D-dimerHS, Werfen Group) and fibrinogen (QFA thrombin, Werfen Group) were measured on an automated coagulometer analyzer, according to manufacturer procedure (ACL TOP500, Werfen Group). Prothrombin fragment 1 + 2 (F1 + 2) was measured using commercially available ELISA (Siemens).

Giaccherini C., Verzeroli C., Russo L., Gamba S., Tartari C.J., Bolognini S., Schieppati F., Ticozzi C., Sarmiento R., Celio L., Masci G., Tondini C., Petrelli F., Giuliani F., D’Alessio A., De Braud F., Santoro A., Labianca R., Gasparini G., Marchetti M, & Falanga A. (2022). Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer. Cancers, 14(18), 4347.

+ Open protocol

+ Expand

Coagulation Biomarkers Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma levels of fibrinogen (QFA thrombin, Werfen Group, Milan, Italy) and FVIII coagulant activity (HemosIL FVIII:c, Werfen Group) were measured according to manufacturer procedure, on an automated coagulometer analyzer (ACL TOP500, Werfen Group). Plasma levels of D-dimer (STA Liatest D-Di PLUS), protein C activity (PC, STA-STAChrom Protein C), and free protein S (free-PS, STA-Liatest Free Protein S) were measured on the STA Compact Max 3 coagulation analyzer. Plasma levels of prothrombin fragment 1 + 2 (F1 + 2) were measured using a commercially available ELISA (Enzygnost^®, Siemens Healthcare Diagnostics, Munich, Germany).

Gomez-Rosas P., Giaccherini C., Russo L., Verzeroli C., Gamba S., Tartari C.J., Bolognini S., Ticozzi C., Schieppati F., Barcella L., Sarmiento R., Masci G., Tondini C., Petrelli F., Giuliani F., D’Alessio A., Minelli M., De Braud F., Santoro A., Labianca R., Gasparini G., Marchetti M, & Falanga A. (2023). A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients. Cancers, 15(18), 4588.

+ Open protocol

+ Expand

Coagulation Biomarkers in Healthy Controls

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma levels of D-dimer (HemosIL D-dimerHS, Werfen Group) and fibrinogen (QFA thrombin, Werfen Group) were measured on an automated coagulometer analyzer (ACL TOP500, Werfen Group). F1+2 (Siemens Healthcare Diagnostics) and FVIIa-AT complex (Stago) were determined by commercial ELISA. Reference intervals for coagulation biomarkers were internally generated from a group of 200 apparently healthy controls (170 females; 30 males) with no chronic or acute diseases. Median age was 49 years (range, 35-64 years).

Giaccherini C., Marchetti M., Masci G., Verzeroli C., Russo L., Celio L., Sarmiento R., Gamba S., Tartari C.J., Diani E., Vignoli A., Malighetti P., Spinelli D., Tondini C., Barni S., Giuliani F., Petrelli F., D’Alessio A., Gasparini G., De Braud F., Santoro A., Labianca R, & Falanga A. (2020). Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica, 105(6), 1704-1711.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!